NL8003871A - Farmaceutische samenstelling met als actieve component extracten van hedera helix en werkwijze voor het winnen van de extracten. - Google Patents
Farmaceutische samenstelling met als actieve component extracten van hedera helix en werkwijze voor het winnen van de extracten. Download PDFInfo
- Publication number
- NL8003871A NL8003871A NL8003871A NL8003871A NL8003871A NL 8003871 A NL8003871 A NL 8003871A NL 8003871 A NL8003871 A NL 8003871A NL 8003871 A NL8003871 A NL 8003871A NL 8003871 A NL8003871 A NL 8003871A
- Authority
- NL
- Netherlands
- Prior art keywords
- extract
- hederasaponin
- hedera helix
- extracts
- hederine
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims description 54
- 240000008669 Hedera helix Species 0.000 title claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 238000000034 method Methods 0.000 title description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 239000000047 product Substances 0.000 claims description 23
- RYHDIBJJJRNDSX-MCGLQMIESA-N Hederacoside C Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@@H](CC(C)(C)CC3)C=3[C@@]([C@]5(C)CC[C@H]6[C@](C)(CO)[C@@H](O[C@H]7[C@@H]([C@@H](O)[C@@H](O)CO7)O[C@H]7[C@@H]([C@H](O)[C@@H](O)[C@H](C)O7)O)CC[C@]6(C)[C@H]5CC=3)(C)CC4)O2)O)[C@H](O)[C@H]1O RYHDIBJJJRNDSX-MCGLQMIESA-N 0.000 claims description 20
- MLWBUURUTWPMOO-UHFFFAOYSA-N Hederasaponin C Natural products CC1OC(OC2C(O)COC(OC3CCC4(C)C(CCC5(C)C4CC=C6C7CC(C)(C)CCC7(CCC56C)C(=O)OC8OC(COC9OC(CO)C(OC%10OC(C)C(O)C(O)C%10O)C(O)C9O)C(O)C(O)C8O)C3(C)CO)C2O)C(O)C(O)C1O MLWBUURUTWPMOO-UHFFFAOYSA-N 0.000 claims description 20
- RYHDIBJJJRNDSX-UHFFFAOYSA-N kalopanax-saponin B Natural products OC1C(O)C(O)C(C)OC1OC1C(CO)OC(OCC2C(C(O)C(O)C(OC(=O)C34C(CC(C)(C)CC3)C=3C(C5(C)CCC6C(C)(CO)C(OC7C(C(O)C(O)CO7)OC7C(C(O)C(O)C(C)O7)O)CCC6(C)C5CC=3)(C)CC4)O2)O)C(O)C1O RYHDIBJJJRNDSX-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 230000000855 fungicidal effect Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000007127 saponification reaction Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 230000002141 anti-parasite Effects 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003096 antiparasitic agent Substances 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 101150029182 Hmmr gene Proteins 0.000 claims 3
- MQFLXLMNOHHPTC-UHFFFAOYSA-N 1-isothiocyanato-9-(methylsulfinyl)nonane Chemical compound CS(=O)CCCCCCCCCN=C=S MQFLXLMNOHHPTC-UHFFFAOYSA-N 0.000 claims 2
- 230000002022 anti-cellular effect Effects 0.000 claims 1
- 230000001532 anti-fungicidal effect Effects 0.000 claims 1
- 230000002609 anti-worm Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229930185042 hederasaponin Natural products 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical compound C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 206010000269 abscess Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 6
- 229960003942 amphotericin b Drugs 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 241000242711 Fasciola hepatica Species 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000208341 Hedera Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000006275 fascioliasis Diseases 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000242722 Cestoda Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000577452 Dicrocoelium Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000869417 Trematodes Species 0.000 description 2
- 241000224526 Trichomonas Species 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960000901 mepacrine Drugs 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- SWDXALWLRYIJHK-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;piperazine Chemical compound C1CNCCN1.OC(=O)CC(O)(C(O)=O)CC(O)=O SWDXALWLRYIJHK-UHFFFAOYSA-N 0.000 description 1
- HSSBORCLYSCBJR-UHFFFAOYSA-N Chloramben Chemical compound NC1=CC(Cl)=CC(C(O)=O)=C1Cl HSSBORCLYSCBJR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001464384 Hymenolepis nana Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000975692 Syphacia obvelata Species 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- TUFPZQHDPZYIEX-UHFFFAOYSA-N alpha-Santonin Natural products C1CC2(C)C=CC(=O)C=C2C2C1C(C)C(=O)O2 TUFPZQHDPZYIEX-UHFFFAOYSA-N 0.000 description 1
- XJHDMGJURBVLLE-BOCCBSBMSA-N alpha-santonin Chemical compound C([C@]1(C)CC2)=CC(=O)C(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 XJHDMGJURBVLLE-BOCCBSBMSA-N 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000001069 nematicidal effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960000718 piperazine citrate Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940074353 santonin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7917451 | 1979-07-05 | ||
| FR7917451A FR2460136B1 (fr) | 1979-07-05 | 1979-07-05 | Compositions pharmaceutiques contenant des extraits de lierre grimpant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8003871A true NL8003871A (nl) | 1981-01-07 |
Family
ID=9227547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8003871A NL8003871A (nl) | 1979-07-05 | 1980-07-04 | Farmaceutische samenstelling met als actieve component extracten van hedera helix en werkwijze voor het winnen van de extracten. |
Country Status (13)
| Country | Link |
|---|---|
| AT (1) | AT369264B (enExample) |
| BE (1) | BE884190A (enExample) |
| CH (1) | CH647787A5 (enExample) |
| DE (1) | DE3025223A1 (enExample) |
| ES (1) | ES493118A0 (enExample) |
| FR (1) | FR2460136B1 (enExample) |
| GB (1) | GB2051575B (enExample) |
| GR (1) | GR69637B (enExample) |
| IE (1) | IE50062B1 (enExample) |
| IT (1) | IT1132510B (enExample) |
| LU (1) | LU82583A1 (enExample) |
| NL (1) | NL8003871A (enExample) |
| PT (1) | PT71495A (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1195849B (it) * | 1986-07-01 | 1988-10-27 | Sigma Tau Ind Farmaceuti | Saponine triterpeniche ad attivita' antiinfiammatoria,mucolitica ed antiedemigena,procedimento per il loro ottenimento e composizioni farmaceutiche che li comprendono |
| DE4010042A1 (de) * | 1990-03-29 | 1991-10-24 | Cassella Ag | Verwendung von efeu zur topischen behandlung vermehrter schuppenbildung der behaarten und unbehaarten haut sowie der psoriasis |
| WO2004089357A2 (en) * | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| DE10335173A1 (de) * | 2003-07-30 | 2005-03-03 | Mirjana Kiener | Mittel zur Vergrösserung der weiblichen Brust |
| DE10345342A1 (de) * | 2003-09-19 | 2005-04-28 | Engelhard Arzneimittel Gmbh | Verfahren zur Herstellung eines lagerstabilen Extraktes aus Efeublättern, sowie ein nach diesem Verfahren hergestellter Extrakt |
| DE10345343A1 (de) | 2003-09-19 | 2005-04-14 | Engelhard Arzneimittel Gmbh & Co. Kg | Verfahren zur Herstellung eines Extrakts aus Efeublättern und nach diesem Verfahren hergestellter Extrakt |
| GB0724967D0 (en) * | 2007-12-21 | 2008-01-30 | Univ Bangor | Composition and method |
| GB201404505D0 (en) * | 2013-09-06 | 2014-04-30 | Mars Inc | Oral anti-parasitic composition |
| EP3939596A1 (en) * | 2020-07-14 | 2022-01-19 | Bimeda Animal Health Limited | A composition for treating helminth infestation in a mammal |
| CN114805466B (zh) * | 2022-04-15 | 2023-06-20 | 湖南朗林生物资源股份有限公司 | 一种常春藤提取物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6330E (fr) * | 1905-06-14 | 1906-10-13 | Petrus Johannes Portman | Dispositif automatique avec appareil de controle pour la sécurité de la circulation des chemins de fer |
| BE670523A (enExample) * | 1964-10-09 | |||
| FR6218M (enExample) * | 1967-05-24 | 1968-07-29 | ||
| FR2233071A1 (en) * | 1973-06-14 | 1975-01-10 | Prod Hyg Laboratoires | Flavones and saponins extracted from ivy - by solid-liquid extraction of undesirables followed by alcohol extraction |
-
1979
- 1979-07-05 FR FR7917451A patent/FR2460136B1/fr not_active Expired
-
1980
- 1980-07-03 DE DE19803025223 patent/DE3025223A1/de not_active Withdrawn
- 1980-07-04 AT AT0350580A patent/AT369264B/de not_active IP Right Cessation
- 1980-07-04 GR GR62377A patent/GR69637B/el unknown
- 1980-07-04 LU LU82583A patent/LU82583A1/fr unknown
- 1980-07-04 ES ES493118A patent/ES493118A0/es active Granted
- 1980-07-04 IE IE1393/80A patent/IE50062B1/en unknown
- 1980-07-04 NL NL8003871A patent/NL8003871A/nl not_active Application Discontinuation
- 1980-07-04 CH CH5153/80A patent/CH647787A5/fr not_active IP Right Cessation
- 1980-07-04 GB GB8021943A patent/GB2051575B/en not_active Expired
- 1980-07-04 PT PT71495A patent/PT71495A/pt unknown
- 1980-07-04 IT IT23262/80A patent/IT1132510B/it active
- 1980-07-04 BE BE0/201310A patent/BE884190A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES8103974A1 (es) | 1981-04-01 |
| FR2460136A1 (fr) | 1981-01-23 |
| DE3025223A1 (de) | 1981-01-08 |
| LU82583A1 (fr) | 1980-10-08 |
| PT71495A (fr) | 1980-08-01 |
| CH647787A5 (fr) | 1985-02-15 |
| IT1132510B (it) | 1986-07-02 |
| FR2460136B1 (fr) | 1986-01-10 |
| IE50062B1 (en) | 1986-02-05 |
| GB2051575B (en) | 1984-01-18 |
| IE801393L (en) | 1981-01-05 |
| BE884190A (fr) | 1981-01-05 |
| ES493118A0 (es) | 1981-04-01 |
| IT8023262A0 (it) | 1980-07-04 |
| AT369264B (de) | 1982-12-27 |
| GR69637B (enExample) | 1982-07-06 |
| ATA350580A (de) | 1982-05-15 |
| GB2051575A (en) | 1981-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5908857A (en) | Agent for the treatment of infections | |
| CN112979743B (zh) | 白桦脂酸衍生物及其应用 | |
| NL8003871A (nl) | Farmaceutische samenstelling met als actieve component extracten van hedera helix en werkwijze voor het winnen van de extracten. | |
| EP0015175B1 (fr) | Médicament constitué de Pichia ou d'extraits de Pichia | |
| DE3318989A1 (de) | Ss,(gamma)-dihydropolyprenylalkoholderivate und arzneimittel, welche diese enthalten | |
| EP0054486A1 (fr) | Composition pharmaceutique à usage topique à base d'un extrait total d'Hedysarum Fructescens Willd (lespedeza capitata michaux) | |
| CN117942324A (zh) | 酚类化合物在抑制细胞铁死亡和防治铁死亡相关疾病中的应用 | |
| JPH0753359A (ja) | リポキシゲナーゼ阻害剤 | |
| JPH0778021B2 (ja) | 下痢症ウイルス感染阻害剤 | |
| CN117447471B (zh) | 一种吲哚二酮哌嗪类化合物及其制备方法和在制备破骨细胞分化抑制剂中的应用 | |
| DE3031788C2 (enExample) | ||
| JP2599163B2 (ja) | 家畜および家禽のサルモネラ・テイフィムリウム感染症の予防及び治療剤 | |
| CN105534971B (zh) | 二苯并氧杂环庚三烯类化合物在体外筛选或制备药物中的应用 | |
| CN1329900A (zh) | 用于改善造血功能的茯苓提取物,含它们的药物组合物及制备方法 | |
| JPS63295512A (ja) | 制ガン剤 | |
| US3947479A (en) | Reduction of serum lipid levels, and agents and compositions useful therefor | |
| CN104147006A (zh) | 盐酸去亚甲基小檗碱在制备预防和/或治疗异烟肼致药源性肝损伤药物中的应用 | |
| CN115490757B (zh) | 活性氧自由基响应的多粘菌素前药化合物及其应用 | |
| CN108276468B (zh) | 一种甘草次酸酯及其制备方法和在制备抗病毒药物中的应用 | |
| JP2005523301A (ja) | Ｂａｒｌｅｒｉａｐｒｉｏｎｉｔｉｓｌｉｎｎからの抽出物を含む製薬組成物、およびその調製方法 | |
| JPH01287036A (ja) | 発癌プロモーター抑制剤 | |
| JP2599155B2 (ja) | 鳥類の大腸菌症の予防及び治療剤 | |
| CH652386A5 (fr) | Derives d'acides phenyl aliphatique carboxyliques comme medicaments. | |
| TWI527828B (zh) | 新穎的三萜化合物及其用途 | |
| KR100202757B1 (ko) | 당뇨병 치료제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |